Sprifermin

Sprifermin (INN) (developmental code name AS-902330), also known as recombinant human fibroblast growth factor 18 (rhFGF18), is a recombinant form of human fibroblast growth factor 18 (FGF18)[1]:45 which is under development by Merck and Nordic Bioscience for the treatment of osteoarthritis.[2] As a recombinant form of FGF18, sprifermin is a potent agonist of the FGFR2 and FGFR3.[3][4]

Sprifermin
Clinical data
Other namesAS-902330; rhFGF18; L-Methionyl(human fibroblast growth factor 18 (FGF-18, zFGF5)-(1-169)-peptide)[1]:45
Identifiers
CAS Number
UNII
Chemical and physical data
FormulaC876H1396N258O256S6
Molar mass19830.71 g·mol−1
3D model (JSmol)

As of 2017, the drug is in phase II clinical trials for the treatment of osteoarthritis.[2][5]

2019 outcomes of phase 2 clinical trial for KOA, shows improvement in cartilage thickness, but fails to satisfy tests like the WOMAC, therefore failing to satisfy its primary end points.[6]

However in some subgroups where cartilage thickness is of specific concern, clinical significance might be achieved.[7]

References

  1. "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). World Health Organization.
  2. "Sprifermin - Merck". Adis Insight. Springer Nature Switzerland AG.
  3. Barrett KE, Ghishan FK, Merchant JL, Said HM, Wood JD (10 May 2006). Physiology of the Gastrointestinal Tract. Academic Press. pp. 216–. ISBN 978-0-08-045615-7.
  4. Said HM (4 July 2012). Physiology of the Gastrointestinal Tract, Two Volume Set. Academic Press. pp. 235–. ISBN 978-0-12-382027-3.
  5. Clinical trial number NCT01919164 for "A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin (AS902330) in Patients With Osteoarthritis of the Knee (FORWARD)" at ClinicalTrials.gov
  6. Hochberg MC, Guermazi A, Guehring H, Aydemir A, Wax S, Fleuranceau-Morel P, et al. (October 2019). "Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial". JAMA. 322 (14): 1360–1370. doi:10.1001/jama.2019.14735. PMC 6784851. PMID 31593273.
  7. Gühring H, Kraines J, Moreau F, Daelken B, Ladel C, Wirth W, Conaghan PG, Eckstein F, Hochberg M (2019-06-01). "Op0010 Cartilage Thickness Modification with Sprifermin in Knee Osteoarthritis Patients Translates into Symptomatic Improvement Over Placebo in Patients at Risk of Further Structural and Symptomatic Progression: Post-Hoc Analysis of the Phase Ii Forward Trial". Annals of the Rheumatic Diseases. 78 (Suppl 2): 70–71. doi:10.1136/annrheumdis-2019-eular.1216. ISSN 0003-4967.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.